The choice of TZ as recognition element offers a double advantage, as it drives the specific binding to the membrane biomarker HER2 and is a standard of care for HER2 + BC patients because it is often administered as part of the adjuvant therapy after surgery to reduce the risk of recurrence [41, 42]. The gene discussed is ERBB2; the disease is breast cancer.